Several valuation models suggest the stock is significantly undervalued. Discounted Cash Flow (DCF) analyses from Yahoo Finance estimate the stock is trading at a ~52-53% discount to its fair value.
As of late April 2026, the consensus among financial analysts for leans toward a Hold , though it remains a polarizing "value" play with significant long-term upside potential. The "Buy" Case: Long-Term Growth & Valuation gsk buy or sell
For investors with a longer time horizon, GSK presents a compelling "Buy" narrative centered on its successful pivot to a high-margin, pure-play pharmaceutical company: Several valuation models suggest the stock is significantly